TERTrific hormones promote hematopoiesis

Haneline, Laura S.

doi:10.1182/blood-2009-07-231787

Search citation statements

Order By: Relevance

Paper Sections

Select...

Erythrocytosis and Polycythemia As Adverse Drug Events Durin1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

2015

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…showed that under the influence of estradiol, ERα binds to a promoter located on the TERT gene and increases transcription. This leads to an increase in telomerase stability, which may ultimately increase hematopoietic stem cell proliferation and survival [66,67]. This hypothesis, in conjunction with the observations made by Bachman et al., may best describe the systemic processes that lead to an increase in Hb and Hct during TRT (Figure ).…”

Section: Erythrocytosis and Polycythemia As Adverse Drug Events Durinmentioning

confidence: 85%

Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male

Jones¹,

Dukovac²,

Sangkum³

et al. 2015

Sexual Medicine Reviews

View full text Add to dashboard Cite

Section: Erythrocytosis and Polycythemia As Adverse Drug Events Durinmentioning

confidence: 85%

Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male

Jones¹,

Dukovac²,

Sangkum³

et al. 2015

Sexual Medicine Reviews

View full text Add to dashboard Cite

Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches

Füreder

Valent

2011

Leukemia & Lymphoma

View full text Add to dashboard Cite

In a substantial number of patients with aplastic anemia (AA), immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine A (CSA) leads to long-lasting remissions and is thus regarded as standard therapy. However, no consensus exists on how to treat refractory or relapsed AA, especially when no related stem cell donor is available. For selected patients, matched unrelated donor stem cell transplant (MUDSCT) is an option. In addition, umbilical cord blood and haploidentical donors have been considered as an alternative source of stem cells. Patients without a suitable donor may benefit from a second cycle of ATG and CSA. Alternatives are alemtuzumab and high dose cyclophosphamide, both of which induce remission in more than 50% of patients with relapsed AA. Further experimental drugs are androgens, hematopoietic growth factors (interleukins IL-3, IL-6, and IL-11 and stem cell factor [SCF]), and the tumor necrosis factor (TNF)-targeting agent etanercept. Clinical trials with these agents are ongoing and will explore long-term outcomes and potential beneficial effects of drug combinations.

show abstract

TERTrific hormones promote hematopoiesis

Cited by 2 publications

References 6 publications

Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male

Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male

Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches

Contact Info

Product

Resources

About